Public consultation on items to be considered by the PBAC (July 2022)

Closed 25 May 2022

Opened 30 Mar 2022


Consultation is now open for items listed on the July 2022 PBAC agenda.

The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. 

The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant.

  • Input can be submitted via the online survey.  A copy of the questions asked in the survey can be downloaded below under ‘Related’ to assist your preparation.
  • There is the option to upload a file with your submission. The preferred file types are PDF or Microsoft Word, however other file types will be accepted, provided they are no larger than 25mb. If your file is too large, or you wish to upload more than one file, please contact
  • You can save and come back at any time to your response before the consultation close date.
  • Once you have submitted, a copy of your submission will be emailed to the contact email address provided.

Should you wish to provide input on another medicine, you will need to start a new survey.

Please note that we may be updating this survey in the coming months to provide additional guidance and welcome suggestions on ways to further improve this process.

What happens next

PBAC Outcomes are published to inform the public about the PBAC’s advice to the Minister for Health. The documents report the PBAC’s recommendation in each case and summarise the reasons for the advice. 

The PBAC outcomes  are available on the PBS website six (6) weeks after each PBAC meeting and can be found using the Medicine Status Website.

Further explanation of the PBAC outcome is available in the Public Summary Document. Public Summary Documents are available on the PBS website  approximately four (4) months after the PBAC meeting. See the PBAC calendar  for publication dates.


  • Anyone from any background


  • All